Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: As ...

In this series, we measure how swiftly a company turns cash into goods or services and back into cash. We'll use a quick, relatively foolproof tool known as the cash conversion cycle, or CCC for short ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Abaxis, Inc. ABAX has been gaining investor confidence on consistently positive results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 67.8% ...

UNION CITY, Calif., Oct. 31, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced the Company has signed ...

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside ...

Abaxis (Nasdaq: ABAX) is expected to report Q4 earnings on April 25. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year quarter, average ...

For the quarter, Abaxis reported that revenues grew 9% year-over-year to $57.7 million. The company’s veterinary revenues were up 10% to $47.7 million, it said in a press release. But net income was ...

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not ...

Shares of Abaxis, Inc.ABAX scaled a new 52-week high of $78.53 on Jan 29, closing lower at $76. The company has gained 62.7% in the last six months, way higher than the broader industry 's gain of ...

Abaxis (ABAX) reported its second straight earnings miss on October 22 as revenue came in below expectations and profit margins contracted. Analysts revised their estimates meaningfully lower for both ...

Zoetis said it would buy Abaxis, a maker of veterinary diagnostic instruments, for about $1.9 billion in cash. The deal will bolster the Animal health company's position in the fast-growing ...